Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

As the nation's largest organization serving the critical needs of blood cancer patients, we are alarmed by recent actions ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic progenitors as well as leukemic cells. However, in its current form, the manuscript is inadequate ...